CMS posted the 2027 Medicare Advantage star ratings on Thursday evening, October 8, and the managed-care sector woke up with a clear winner and a clear loser. Humana jumped roughly 13% in after-hours trade. Alignment Healthcare fell about 23%. CVS slipped around 4%. Three different results, one shared cause: a quality scorecard that determines who collects federal bonus payments in 2028.

The question for investors this morning is not whether Humana’s result was good. It was very good. The question is whether a 13% overnight move already prices what the recovery is actually worth.

Why This Star Rating Hit Differently

Humana’s flagship contract, H5216, covers about 2.4 million members. In the 2027 ratings published by CMS, that contract climbed from 3.5 stars to 4.0, crossing the threshold that unlocks federal quality bonus payments. The improvement restores eligibility for bonus income that will flow through Humana’s financials in 2028.

To understand why the market reacted so sharply, you need the context of how far Humana fell. In October 2024, the share of its members enrolled in plans rated 4 stars or higher collapsed from 94% to 25%, and the earnings damage was severe: adjusted EPS guidance for 2026 dropped to at least $9.00, down from $17.14 for 2025. The company has also said that a half-star swing on a contract of this scale can move bonus dollars by hundreds of millions per year.

Last night’s result does not fully reverse two years of pain, but it reopens the door. CEO Jim Rechtin has been targeting a return to stronger Star performance by the 2028 bonus year, and Thursday’s CMS release makes that trajectory materially more credible.

Why Wall Street Is Paying Attention

The analyst community had been building toward this moment for weeks. Barclays upgraded Humana to Overweight with a $515 price target ahead of the release. Cantor Fitzgerald moved to Overweight the day before CMS published, raising its 2028 EPS estimate to $28.27 and its price target to $460. Then this morning, Baird upgraded to Outperform and raised its target to $596, projecting Humana can achieve adjusted EPS of more than $35 in 2028, representing roughly 99% compound annual growth from 2026 to 2028. Wolfe Research lifted its target to $450.

The spread between those targets, $460 to $596, tells you analysts agree on the direction but disagree sharply on the magnitude. That spread is the real investment question.

What’s Driving the Opportunity

The 2027 ratings will feed into 2028 bonus payments from CMS, not 2026 or 2027 revenue. Alignment Healthcare confirmed this in its 8-K filed Thursday night, noting the downgrade is not expected to impact revenue for fiscal years 2026 or 2027. The same timing logic applies in Humana’s favor: the bonus cash does not arrive immediately, but the market prices expected cash flows, and the market had been pricing a limited bonus recovery.

Baird frames the margin math explicitly: individual Medicare Advantage margins should expand from roughly breakeven today to more than 3% in 2028, supported by improved star performance, conservative bids, and decelerating national cost trends. Cantor Fitzgerald’s Humana bull case sees 2027 EPS potentially reaching $17.96, well above the $9.00 2026 baseline, before the 2028 bonus tailwind even fully arrives.

What Could Go Wrong

The after-hours move pushed HUM above its prior 52-week high of $428.88. Before Thursday’s close the stock was trading at $387.12. A 13% overnight gain on a name that had already recovered more than 130% from its 2026 lows raises a legitimate valuation question.

The bonus payments are real, but they are two years away. CMS methodologies can shift. Alignment Healthcare’s downgrade illustrates exactly how a plan that looked bulletproof in the 2026 rating year, with the company previously saying effectively all members were in 4-star-or-better plans, can still lose the bonus line on a single contract in one rating cycle. Humana’s H5216 contract cleared 4.0 stars, but the durability of that improvement is what will matter most across future cycles.

Execution risk remains. Humana has been shrinking its membership footprint deliberately under CEO Rechtin’s margin-over-membership strategy, exiting plans expected to affect roughly 600,000 members for 2027. Fewer members earning bonuses means the bonus dollar impact, while meaningful, is smaller than it would have been at peak enrollment.

The Bottom Line

Humana is the most compelling managed-care stock on the board today because it owns a concrete, verifiable catalyst with a known financial mechanism. The 2027 star rating improvement on H5216 is not a rumor or an analyst forecast. CMS published it. The 2028 bonus payments are highly likely absent another ratings reversal.

The fair concern is price. A 13% overnight move on a stock already up sharply from its lows means some of this recovery is priced. But Baird’s $596 target and Cantor’s $460 still imply meaningful upside from current levels, and both are grounded in a 2028 EPS recovery that the market was not pricing six months ago. Investors entering here are not buying a recovery story at the start. They are buying the second chapter, with the thesis now partially confirmed and the largest bonus payments still two years out.